HCA is in a recovery uptrend rather than a clean, sustained advance: the stock is up 6.56% over the past year but down 0.29% year-to-date, a divergence that reflects a sharp mid-year selloff followed by a powerful rebound. At $469.03, the shares sit at roughly 55.6% of the 52-week range between a low of $353.99 and a high of $556.52, meaning price has reclaimed the middle of the band but remains about 15.7% below its 52-week high — positioning that suggests improving momentum rather than overextension, with the prior high still acting as an overhead supply zone. The 33.72% maximum drawdown over the period underscores how violent the earlier decline was, and the current level represents a partial retracement of that damage.

Short-term momentum is decisively positive and accelerating: the stock has gained 7.46% over the past month and 22.72% over three months, with the 3-month figure far outpacing the 6-month gain of 8.46% and the 1-year gain of 6.56%, indicating the bulk of returns were generated recently. This is a clear inflection from the earlier downtrend, and relative strength confirms it — HCA has outperformed the S&P 500 by 8.48 percentage points over one month and a striking 19.87 points over three months, even as its 1-year relative strength of -6.57 points and YTD relative strength of -11.74 points show the stock is still repairing damage done earlier in the year. The most recent session added 0.37% on volume of about 1.03 million shares, a modest tape that suggests the advance is orderly rather than climactic, though the 3.24 short ratio indicates short interest is not trivial and could add fuel to further upside.

Key technical levels are well defined: support sits at the 52-week low of $353.99, roughly 24.5% below the current price, with intermediate support likely in the $400–$410 zone where the stock consolidated in August and September, while resistance is anchored at the 52-week high of $556.52, about 18.7% above current levels. A breakout above the prior high would signal a full trend reversal and likely invite momentum and relative-strength buyers, whereas a breakdown below $400 would undermine the recovery thesis and reopen the path toward the $354 low. With a beta of 1.11, HCA is roughly 11% more volatile than the market — meaningful but not extreme — implying position sizing should account for modestly amplified drawdowns, and the 33.72% max drawdown is a reminder that this is a stock capable of sharp, sentiment-driven moves.

Revenue is growing at a healthy clip and, importantly, appears to be reaccelerating: Q2 2026 revenue reached $20.23 billion, up 8.73% year-over-year from $18.61 billion in Q2 2025, following Q1 2026 revenue of $19.11 billion (up 4.3% from $18.32 billion a year earlier) and Q4 2025 revenue of $19.51 billion (up 6.7% from $18.29 billion). The sequential climb from $19.11 billion to $20.23 billion and the acceleration in the YoY rate point to strengthening procedure volumes and pricing, and the payer mix data shows managed care and other insurers contributing $9.01 billion, managed Medicare $3.42 billion, Medicare $2.93 billion, Medicaid $2.79 billion, and managed Medicaid $1.00 billion — a diversified but government-exposed book where supplemental payment programs are the swing factor. The trajectory supports the investment case for durable mid-to-high-single-digit top-line growth, though the heavy government payer concentration keeps reimbursement policy as the key risk to that growth.

HCA is solidly profitable and margins are trending favorably: Q2 2026 net income was $1.70 billion on a net margin of 8.40%, with gross profit of $3.07 billion (15.16% gross margin) and operating income of $3.07 billion (15.16% operating margin), while EBITDA reached $4.01 billion for a 19.83% EBITDA margin. Comparing sequentially, operating margin improved from 14.98% in Q1 2026 and 15.16% in Q2 2026 versus 15.95% in Q2 2025, while the Q4 2025 quarter showed a notably stronger 16.29% operating margin and 21.29% EBITDA margin — so profitability is healthy but not uniformly expanding, with some quarter-to-quarter noise from payer mix and supplemental payments. The company-level operating margin of 15.83% and net margin of 8.97% are consistent with large-scale hospital operators, where single-digit net margins are typical given high labor and supply costs, and the interest coverage ratio of roughly 5.1x indicates earnings comfortably service the debt load.

Balance-sheet and cash-flow metrics reveal a leveraged but cash-generative business: free cash flow TTM is $5.997 billion, Q2 2026 operating cash flow was $2.335 billion against capital expenditures of $1.231 billion (FCF of $1.104 billion), and the company returned capital aggressively with $2.064 billion of stock repurchased and $171 million of dividends paid in the quarter. The current ratio of 0.83 and quick ratio of 0.69 signal tight near-term liquidity, and the debt-to-equity ratio of -8.33 and negative book value (P/B of -17.87) reflect an equity base eroded by years of buybacks — a capital structure that is intentional but leaves less cushion. ROE of -112.6% is a mechanical artifact of negative equity rather than an operating problem, while ROA of 12.29% is genuinely strong; the key takeaway is that HCA funds growth and buybacks from internal cash flow, but its leverage and thin liquidity mean refinancing conditions and rate levels matter.